Teclistamab Indication Expanded for Multiple Myeloma
The EMA recommended an expanded use of the immunotherapy for patients who have undergone at least one prior treatment.
Updated on Sept. 18, 2026 in Cancer
Live Poll
Do you trust pharmaceutical companies to prioritize affordable access to new cancer therapies?
The European Medicines Agency Committee for Medicinal Products for Human Use recommended an indication extension for TECVAYLI to treat relapsed or refractory multiple myeloma. This recommendation applies to adult patients who have received at least one prior therapy, offering a new treatment pathway for those facing disease progression.
Why it matters
Patients with multiple myeloma often face relapse after initial treatment, creating a critical need for effective immunotherapy options earlier in the care journey. This recommendation potentially broadens access to a therapy that has shown significant benefits in slowing disease progression and extending survival.
In the MajesTEC-9 study, teclistamab monotherapy was compared to standard care regimens in adults with multiple myeloma. Teclistamab patients achieved a 65.9% complete response rate compared to 16.8% in the standard care group, with a median treatment duration of 13.1 months versus 7.0 months.
The players
European Medicines Agency (EMA)
The European Union agency responsible for the scientific evaluation, supervision, and safety monitoring of medicines.
Committee for Medicinal Products for Human Use (CHMP)
The committee within the EMA that prepares opinions on questions concerning medicines for human use.
TECVAYLI
A bispecific antibody therapy developed for the treatment of relapsed or refractory multiple myeloma.
The details
Teclistamab is a subcutaneous bispecific antibody designed to recruit the immune system to fight cancer. By binding simultaneously to BCMA targets on myeloma cells and CD3 receptors on T-cells, the therapy redirects the immune system to identify and destroy malignant cells. The study evaluated this approach against standard regimens including pomalidomide, bortezomib, or carfilzomib combined with dexamethasone.
Timeline
August 2022: Initial European Commission approval for teclistamab.
August 2023: European Commission approved reduced dosing frequency.
August 2026: European Commission approved combination with daratumumab.
September 18, 2026: CHMP recommended the indication extension for TECVAYLI.
Health Landscape
The clinical standard for multiple myeloma treatment is shifting toward earlier use of targeted immunotherapies rather than relying solely on traditional regimens. This recommendation follows the trajectory established by the MajesTEC-9 study, which aims to improve survival outcomes in earlier lines of therapy.
If you or a family member are navigating relapsed multiple myeloma, this development highlights a potential new option for your treatment plan. Discuss with your oncologist whether this therapy aligns with your current medical history and overall prognosis.
The takeaway
Immunotherapy continues to demonstrate significant potential in managing relapsed multiple myeloma by redirecting immune cells to target cancer. Patients should track their disease response and discuss the relevance of emerging indication extensions with their specialized oncology team.
Further reading
For more information on current treatment standards, visit our Cancer section.
More information
Review the full Summary of Product Characteristics for detailed clinical information.
Live Poll
Do you trust pharmaceutical companies to prioritize affordable access to new cancer therapies?
